Infectious Disease Frontier Archives - Page 25 of 35

Dr. Hongzhou Lu: NAD Management is Key for HIV Patients, Not Just Changing Medication

By Mourabit Halima 2024.01.14

The use of highly active antiretroviral therapy (HAART) has led to effective virological control in HIV-infected individuals, significantly reducing mortality rates and transforming AIDS into a treatable and manageable chronic disease. Today, one of the main clinical challenges is how to choose more "efficient and less toxic" treatment options to improve patients' quality of life. At the 12th International AIDS Society HIV Science Conference (IAS 2023) held recently, the first randomized controlled trial on switching to integrase strand transfer inhibitor (INSTI)-based therapy to control weight gain was reported. Infectious Disease Frontier invited Dr. Hongzhou Lu from Shenzhen Third People's Hospital, China, to interpret this trial and share insights into the current and future management of non-AIDS defining diseases (NAD) in HIV-infected individuals.

Dr. Wei Cao: Focus on Managing HIV Complications, Further Improving Patient Survival

By Mourabit Halima 2024.01.14

The 12th International AIDS Society Conference on HIV Science (IAS 2023) was held from July 23-26, 2023, in Brisbane, Australia. As the largest open scientific conference in the global field of HIV/AIDS, it attracted the participation of experts, medical professionals, community organizations, and healthcare companies worldwide. Dr. Wei Cao from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, was invited to attend the conference and was interviewed on-site by Infectious Disease Frontier. We have invited Dr. Cao to share the latest developments emerging from this conference and hot topics related to HIV/AIDS treatment.

Dr. Yun He: The Impact of Rapid ART Initiation on HIV Outcomes

By Mourabit Halima 2024.01.14

The concept of rapid initiation of antiretroviral therapy (ART) has been proposed for nearly 10 years, and many studies have confirmed the long-term benefits of rapid ART initiation. At the 12th International AIDS Society HIV Science Conference (IAS 2023), Thai scholar Sirinya Teeraananchai reported a study on the impact of rapid ART initiation on the health outcomes of People Living with HIV (PLWH). Dr.Yun He from the Third People's Hospital of Shenzhen, China, was specially invited to comment on the study as follows.

Dr. Hui Wang: Second-line treatment choice for children with HIV infection

By Mourabit Halima 2024.01.14

Currently, the choice of second-line antiretroviral therapy (ART) for children infected with HIV is extremely limited. At the12th International AIDS Society HIV Science Conference (IAS 2023), researchers announced the results of a significant clinical study, the CHAPAS-4 ( Abstract No. OALBB0503), focusing on the long-term treatment outcomes of second-line therapy in children with HIV infections. We specially invited Dr. Hui Wang from the Affiliated Second Hospital of Southern University of Science and Technology, China, to provide a brilliant review of this research.

Dr. Biao Zhu: Common Comorbidities in HIV Patients and Their Antiretroviral Therapy

By Mourabit Halima 2024.01.14

Although antiretroviral therapy (ART) has greatly reduced the mortality associated with HIV, the morbidity of non-AIDS-related complications associated with HIV remains high. Therefore, it is crucial to understand and assess clinical decision factors for adjusting ART in the context of suppressed HIV RNA. At the recently concluded 12th International AIDS Society HIV Science Conference ( IAS 2023), Dr. A. Cozzi-Lepri of University College London reported a study (Abstract number: EPB0169) that analyzed and evaluated the risk of ART switches in the context of common comorbidities combined with HIV and suppressed HIV RNA. This journal specially invited Dr. Biao Zhu from the First Affiliated Hospital of Zhejiang University School of Medicine, China, to provide a brilliant review of this research.

Dr. Ana Hoxha: Clinical characteristics and outcomes of MPXV and HIV co-infected patients

By Lisa Cui 2024.01.14

In 2022, about 70 countries/regions around the world reported cases of MPOX. These countries/regions usually have no prior history of MPXV infections, and previous sustained human-to-human transmissions of MPXV were mainly observed in Africa. At the recent 12th International AIDS Society HIV Science Conference (IAS 2023), Dr. Ana Hoxha from the World Health Organization (WHO) presented a special report titled "HIV among MPOX cases: clinical characteristics and outcomes in the WHO global surveillance 2022". The report, based on over 82,000 patients in the WHO's global MPOX surveillance system, detailed the clinical characteristics and outcomes of HIV-infected individuals among the 2022 MPOX cases. Dr. Hoxha was interviewed on-site by Infectious Disease Frontier.

Dr. Jessica Seidelman: Implementation of a blood culture algorithm in emergency department patients as a diagnostic stewardship intervention

By Mourabit Halima 2023.12.10

Blood culture is one of the most important tests in the clinical microbiology laboratory. Blood culture is the gold standard for diagnosing bloodstream infection and bacteremia. However, in the United States, blood cultures are still performed even for emergency patients with a low probability of bacteremia, which may result in a large waste of resources. At IDWeek 2023, a study reported the implementation of a blood culture algorithm in emergency department patients as a diagnostic stewardship intervention.

Multiple HIV Research Achievements by Dr. Yaokai Chen’s Team from Chongqing Public Health Medical Center Was Selected for the 2023 IDWeek

By Mourabit Halima 2023.12.10

The IDWeek in the United States is one of the largest infectious disease academic conferences globally, often referred to as the "Oscars" of the infectious disease field. Numerous cutting-edge research findings would be shared and discussed at this highly anticipated academic event. During the recent 2023 IDWeek, Dr. Yaokai Chen's team from Chongqing Public Health Medical Center had four HIV-related research findings selected for the conference. One of these was presented as a Rapid-Fire Poster, while the other three were included in poster presentations.

IDWeek Commentary | Dr. Hongzhou Lu: Can ” Online Celebrity Weight Loss Drugs” Also Be Used for HIV-Infected Individuals?

By Mourabit Halima 2023.12.10

Experiencing weight gain due to medication" is a common concern for many people living with HIV (PLWH). Some antiretroviral therapy (ART) regimens are associated with weight gain and related metabolic complications. In the field of endocrinology, newer antidiabetic medications like glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used for weight management and have gained popularity. So, are these new weight loss treatments suitable for PLWH experiencing ART-related weight gain? At the 2023 Infectious Diseases Week (IDWeek 2023), two studies on the use of GLP-1 RAs in PLWH and one study of weight control using protease inhibitor switching were presented. Dr. Hongzhou Lu from Shenzhen Third People's Hospital (The Second Hospital Affiliated with the School of Medicine, Southern University of Science and Technology) provides an introduction and commentary on these studies.

IDWEEK Live Interview |Dr. Hardy：Leveraging Stewardship to Promote Narrower-spectrum Antibiotic Use for Low-risk AmpC Enterobacterales

By Mourabit Halima 2023.12.09

AmpC β-lactamases are class C serine β-lactamases that can be produced by a number of Enterobacteriaceae and glucose non-fermenting Gram-negative bacteria. Although AmpC β-lactamases have been associated with the development of third-generation cephalosporin resistance, this risk of AmpC deinhibition is not the same in different enterobacteria. At the recent Infectious Diseases Week 2023 (IDWeek 2023) conference, Professor Megan E. Hardy, a clinical pharmacologist in infectious diseases from the West Virginia University School of Medicine (WVU Medicine) in the United States, orally reported the results of a study titled, "Leveraging Stewardship to Promote Narrower-spectrum Antibiotic Use for Low-risk AmpC Enterobacterales" and shared his fascinating insights in an interview with Infectious Disease Frontier.